The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: BCKDHA (Branched-Chain Keto Acid Dehydrogenase E1 Subunit Alpha)

Gene and Protein Identity

BCKDHA (UniProt: P12694; HGNC:986) encodes the 2-oxoisovalerate dehydrogenase subunit alpha, a mitochondrial enzyme also known as branched-chain alpha-keto acid dehydrogenase E1 component alpha chain (BCKDH E1α). The protein is classified under EC 1.2.4.4 and belongs to the BCKDHA protein family. Key domains include the alpha-ketoacid dehydrogenase E1 component domain (IPR050771), the dehydrogenase E1 domain (IPR001017), and the thiamine diphosphate (ThDP)-binding domain (IPR029061). The gene is located on human chromosome 19q13.2 (OpenTargets Search: -BCKDHA).

The following table provides a summary of the key molecular, biochemical, and disease-related properties of BCKDHA:

Table: This table summarizes the core molecular, biochemical, localization, regulatory, and disease-related properties of human BCKDHA. It is useful as a compact reference for functional annotation and interpretation of BCKDHA in BCAA metabolism and MSUD.

1. Enzymatic Function and Catalytic Mechanism

1.1 Primary Reaction

BCKDHA encodes the α-subunit of the E1 component of the mitochondrial branched-chain α-keto acid dehydrogenase (BCKDH) complex, which catalyzes the rate-limiting and irreversible step in the catabolism of the three branched-chain amino acids (BCAAs): leucine, isoleucine, and valine (bo2024primaryrolesof pages 11-13, mann2021branchedchainaminoacids pages 4-6). The overall reaction performed by the BCKDH complex is the oxidative decarboxylation of branched-chain α-keto acids (BCKAs) — the transamination products of BCAAs — to their corresponding branched-chain acyl-CoA derivatives, with the concomitant release of CO₂ and generation of NADH (bo2024primaryrolesof pages 11-13, szabo2024mitochondrialalphaketoacid pages 1-6). The three specific substrates are α-ketoisocaproate (KIC, derived from leucine), α-keto-β-methylvalerate (KMV, derived from isoleucine), and α-ketoisovalerate (KIV, derived from valine) (mann2021branchedchainaminoacids pages 4-6).

1.2 E1 Component and Thiamine Pyrophosphate Dependence

The E1 component, in which BCKDHA functions, is a heterotetramer consisting of two α-subunits (BCKDHA) and two β-subunits (BCKDHB), forming an α₂β₂ assembly with two functional active sites (bo2024primaryrolesof pages 11-13, szabo2024mitochondrialalphaketoacid pages 6-9). The E1 component requires thiamine pyrophosphate (ThDP/TPP) as an essential cofactor (mann2021branchedchainaminoacids pages 4-6, hawes1995rolesofamino pages 4-5). Structural studies have shown that ThDP adopts a characteristic "V" shape near the active sites, which are buried within the interfaces between subunits (szabo2024mitochondrialalphaketoacid pages 9-13). The pyrophosphate moiety of ThDP is coordinated by the N-terminal domain of one subunit, while the aminopyrimidine moiety is tethered by both the N-terminal and middle domains of an adjacent monomer, establishing functional coupling between subunits (szabo2024mitochondrialalphaketoacid pages 6-9). The E1α subunit provides residues critical for binding the diphosphate portion of thiamine pyrophosphate and associated divalent metal atoms, while E1β subunits contribute residues that bind the thiazolium ring portion (hawes1995rolesofamino pages 4-5).

1.3 Substrate Specificity

The BCKDH E1 component demonstrates broad substrate specificity. Comparative studies of relative maximal reaction rates show that α-ketoisovalerate (KIV) is the preferred substrate (100% relative activity), followed by α-ketoisocaproate (KIC, ~70%), α-ketobutyrate (~50%), α-keto-β-methylvalerate (KMV, ~40%), 4-methylthio-α-ketobutyrate (~30%), and pyruvate (~20%) (szabo2024mitochondrialalphaketoacid pages 1-6). This breadth of substrate acceptance distinguishes BCKDH from the related pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes (szabo2024mitochondrialalphaketoacid pages 1-6).

1.4 Multienzyme Complex Architecture

The BCKDH complex is one of the largest multienzyme assemblies in the mitochondrial matrix, with molecular weights reaching up to ~10 million Daltons across species. It consists of three catalytically active components: E1 (the α-keto acid decarboxylase, encoded by BCKDHA and BCKDHB), E2 (dihydrolipoyl transacylase, encoded by DBT), and E3 (dihydrolipoamide dehydrogenase, encoded by DLD) (szabo2024mitochondrialalphaketoacid pages 6-9, szabo2024mitochondrialalphaketoacid pages 16-19). The E2 component serves as the structural scaffold, forming a 24-meric cubic core that anchors E1 and E3 as peripheral components. The human BCKDH complex typically contains 12 E1 heterotetramers positioned along the core edges and 6 E3 dimers on the faces of the cubic E2 core (szabo2024mitochondrialalphaketoacid pages 16-19). The three catalytic sites are connected via flexible lipoylated arms extending from the E2 core structure, which shuttle reaction intermediates between the E1, E2, and E3 active sites during the multi-step catalytic cycle (szabo2024mitochondrialalphaketoacid pages 9-13).

2. Subcellular Localization

BCKDHA is synthesized as a precursor protein containing an N-terminal mitochondrial targeting signal peptide (reported at 27 amino acids) that directs the protein to the mitochondrial matrix. Subcellular fractionation experiments and colocalization with MitoTracker Deep Red staining in isolated cardiomyocytes have confirmed that the BCKDH complex, including BCKDHA, resides in the mitochondrial matrix (weiss2024mitolnccontrolscardiac pages 14-15, weiss2024mitolnccontrolscardiac pages 10-12). RNA in situ hybridization-proximity ligation assays (rISH-PLA) have further demonstrated that BCKDHA interactions occur outside the nucleus and overlap with mitochondrial markers (weiss2024mitolnccontrolscardiac pages 10-12). The complex functions at the inner mitochondrial compartment, where BCAA catabolism generates acyl-CoA intermediates that can feed into the TCA cycle and β-oxidation pathways (bo2024primaryrolesof pages 11-13).

3. Regulatory Mechanisms

3.1 Phosphorylation-Based Regulation

The activity of the BCKDH complex is primarily controlled through reversible phosphorylation of the E1α subunit (BCKDHA) at Serine 293 (Ser293), the canonical inhibitory phosphorylation site (mann2021branchedchainaminoacids pages 9-11, hawes1995rolesofamino pages 1-1). Phosphorylation is catalyzed by branched-chain α-ketoacid dehydrogenase kinase (BCKDK/BDK), which inactivates the complex, while dephosphorylation by the mitochondrial protein phosphatase PPM1K (also known as PP2Cm) reactivates it (bo2024primaryrolesof pages 13-15, mann2021branchedchainaminoacids pages 9-11). Mutagenesis studies have revealed that phosphorylation at Ser293 disrupts the active site by placing a negatively charged phosphate group near the thiamine pyrophosphate binding domain, preventing cofactor reconstitution and abolishing enzymatic activity (hawes1995rolesofamino pages 4-5). Alanine substitution of Ser293 increases substrate Km values without affecting Vmax, indicating this residue plays a role in substrate binding rather than catalysis per se (hawes1995rolesofamino pages 4-5). A phosphomimetic S293E mutation results in complete loss of activity and failure to reconstitute with TPP (hawes1995rolesofamino pages 4-5). A second phosphorylation site at Ser303 has also been identified (mann2021branchedchainaminoacids pages 9-11).

Specific residues surrounding Ser293 are critical for kinase recognition: Arg288 is essential for BDK-mediated phosphorylation, while His292 and Asp296 are required for catalytic activity (hawes1995rolesofamino pages 1-1). Thiamine pyrophosphate inhibits phosphorylation of most E1 mutant enzymes, indicating the phosphorylation site region overlaps with the TPP binding domain (hawes1995rolesofamino pages 1-1).

3.2 Tissue-Specific Regulation

The tissue-specific expression patterns of BCKDK and PPM1K create differential BCKDH activity states across organs. Skeletal muscle expresses high levels of BCKDK but low BCKDH complex abundance, resulting in predominantly phosphorylated (inactive) BCKDH that preserves BCKAs for re-amination to BCAAs and protein synthesis (bo2024primaryrolesof pages 13-15, mann2021branchedchainaminoacids pages 9-11). Conversely, liver expresses low BCKDK levels, enabling constitutive BCKDH activation for gluconeogenesis and ketogenesis from BCAA carbon skeletons (bo2024primaryrolesof pages 13-15). PPM1K shows high expression in brain, heart, kidney, diaphragm, and liver, but lower levels in skeletal muscle, further contributing to tissue-specific BCAA catabolism patterns (bo2024primaryrolesof pages 15-16).

3.3 Allosteric Regulation and Metabolon Formation

Recent work has uncovered novel regulatory mechanisms for the BCKDH complex. Weiss et al. (2024) identified mitolnc, a nuclear-encoded long non-coding RNA localized in mitochondria, as an allosteric activator of the BCKDH complex in cardiomyocytes. Mitolnc directly interacts with BCKDHA and other BCKDH subunits, enhancing enzymatic activity independently of phosphorylation status (weiss2024mitolnccontrolscardiac pages 14-15, weiss2024mitolnccontrolscardiac pages 12-14). Loss of mitolnc reduces BCKDH complex activity in the heart, leading to accumulation of BCAAs (particularly leucine), hyperactivation of mTOR signaling, and cardiac hypertrophy (weiss2024mitolnccontrolscardiac pages 14-15, weiss2024mitolnccontrolscardiac pages 10-12). This mechanism provides an explanation for how BCKDH can maintain high activity in the heart despite relatively high BDK-mediated phosphorylation (weiss2024mitolnccontrolscardiac pages 14-15).

Additionally, BCAT2 (branched-chain aminotransferase 2) physically interacts with the BCKDH E1 subunit to form a metabolon that facilitates substrate channeling of BCKAs directly from the transamination enzyme to the decarboxylation complex (blair2021wholebodymetabolicfate pages 3-4, mann2021branchedchainaminoacids pages 9-11). BCAT2 binding to BCKDH increases decarboxylation rates, and this interaction is dynamically regulated — phosphorylation of BCKDH destabilizes the BCAT2–BCKDH association (blair2021wholebodymetabolicfate pages 3-4). Absence of BCAT2 abolishes BCKDH activity, underscoring the functional interdependence of these enzymes (bo2024primaryrolesof pages 11-13).

BCKAs themselves also participate in regulatory feedback: α-ketoisocaproate (KIC) and α-ketoisovalerate (KIV) allosterically inhibit BCKDK, thereby promoting BCKDH dephosphorylation and activation when BCKA levels are elevated (mann2021branchedchainaminoacids pages 9-11, weiss2024mitolnccontrolscardiac pages 10-12).

4. Metabolic Pathway Context

4.1 BCAA Catabolic Pathway

BCKDHA operates at the second and rate-limiting step of BCAA catabolism. The first step is the reversible transamination of BCAAs (leucine, isoleucine, valine) by branched-chain aminotransferases (BCAT1 in cytosol, BCAT2 in mitochondria) to their corresponding BCKAs, with concomitant conversion of α-ketoglutarate to glutamate (bo2024primaryrolesof pages 11-13). The BCKDH complex then performs the irreversible oxidative decarboxylation of BCKAs to branched-chain acyl-CoA intermediates (isovaleryl-CoA, α-methylbutyryl-CoA, and isobutyryl-CoA), which subsequently undergo further catabolism through pathways analogous to β-oxidation of fatty acids (bo2024primaryrolesof pages 11-13, mann2021branchedchainaminoacids pages 4-6). The downstream products ultimately include acetyl-CoA and succinyl-CoA, which feed into the TCA cycle for energy production (cai2026branchedchainaminoacid pages 3-5).

4.2 Integration with Other Metabolic Pathways

Recent research has revealed that BCKDH activity is linked to lipid metabolism through the BCKDH kinase/phosphatase system. White et al. (2018) demonstrated that the BDK and BDP (PP2Cm) integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase (ACLY), connecting BCAA catabolism to de novo lipogenesis (flach2023smallmoleculebranchedchain pages 1-2). In the heart, the major metabolic fate of BCKAs is reamination back to BCAAs rather than oxidation, partly due to low expression of the mitochondrial BCAA transporter SLC25A44 (walejko2021branchedchainαketoacidsare pages 1-2). Elevated BCKA levels activate protein synthesis pathways including 4E-BP1 and MEK-ERK signaling, contributing to pathologic cardiac hypertrophy in obesity (walejko2021branchedchainαketoacidsare pages 1-2).

5. Disease Associations

5.1 Maple Syrup Urine Disease (MSUD)

The primary Mendelian disease caused by BCKDHA mutations is maple syrup urine disease type 1A (MSUD; OMIM #608348), an autosomal recessive inborn error of metabolism. MSUD results from deficient BCKDH complex activity, leading to toxic accumulation of BCAAs and their corresponding BCKAs in blood and tissues (margutti2020maplesyrupurine pages 2-4, campanholi2021molecularbasisof pages 1-2). OpenTargets data confirm strong disease-target association scores (0.84–0.87) for BCKDHA with MSUD and hereditary disease categories (OpenTargets Search: -BCKDHA).

MSUD is classified into several clinical subtypes based on residual enzyme activity and disease severity: classic (the most severe form with <3% residual activity, presenting in the neonatal period), intermediate, intermittent, and thiamine-responsive forms (campanholi2021molecularbasisof pages 1-2). Classic MSUD typically presents within the first two weeks of life with poor feeding, vomiting, lethargy, seizures, hypotonia, and a characteristic maple syrup odor in urine, and can progress to encephalopathy and death if untreated (li2023identificationofgene pages 4-6, sun2020identificationofeight pages 4-5). Multiple types of pathogenic BCKDHA mutations have been identified, including missense, nonsense, frameshift, and splice-site mutations (margutti2020maplesyrupurine pages 2-4, sun2020identificationofeight pages 4-5). Structurally, many disease-causing missense mutations alter protein conformation; for example, the p.Gly281Arg mutation causes steric hindrance altering the β-turn conformation, while the p.A220V mutation changes the side chain structure (li2023identificationofgene pages 4-6, fang2021geneticanalysisby pages 4-5). No clear genotype-phenotype correlations have been established, although mutations within functional domains may lead to more severe disease (margutti2020maplesyrupurine pages 2-4, campanholi2021molecularbasisof pages 1-2).

5.2 Cardiometabolic Disease

Impaired BCKDH activity is implicated in cardiovascular disease. In dilated cardiomyopathy, cardiac BCAA levels are elevated with decreased mitochondrial BCAT2 and BCKDH expression (du2022theroleof pages 6-7). BDK inhibitors such as BT2 and PF-07208254 have shown therapeutic promise by reducing phosphorylated BCKDHA levels, lowering circulating BCAAs and BCKAs, and improving cardiac function (fractional shortening and ejection fraction) in mouse models of heart failure induced by transverse aortic constriction (flach2023smallmoleculebranchedchain pages 1-2, du2022theroleof pages 6-7). BT2 promotes BCKDH dephosphorylation and activation by causing dissociation of BCKDK from the BCKDH complex (du2022theroleof pages 6-7).

5.3 Cancer

BCAA metabolic reprogramming involving BCKDHA is increasingly recognized in oncology. In pancreatic ductal adenocarcinoma (PDAC), BCKDHA is significantly upregulated compared to normal pancreatic cells, and its knockdown selectively impairs tumor growth by inhibiting fatty acid synthesis while maintaining TCA cycle function, indicating that PDAC utilizes BCAA-derived carbon specifically for lipogenesis to support proliferation (cai2026branchedchainaminoacid pages 5-7). In triple-negative breast cancer (TNBC), the relationship is inverse: high BCKDK expression (indicating suppressed BCKDH activity) correlates with worse relapse-free survival and increased aggressiveness, while high BCKDH phosphatase activity correlates with better outcomes (cai2026branchedchainaminoacid pages 5-7). Elevated BCKDK expression has also been observed in hepatocellular carcinoma, promoting metastasis through ERK signaling (li2025proteinlipoylationin pages 3-4, cai2026branchedchainaminoacid pages 27-28). These findings highlight the tumor type-specific heterogeneity in BCAA metabolic reprogramming, with some cancers increasing BCKDH activity for energy and biosynthetic precursors and others suppressing it to accumulate BCAAs for sustained mTORC1 signaling (cai2026branchedchainaminoacid pages 3-5).

5.4 Diabetes and Metabolic Syndrome

Elevated circulating BCAAs are consistently associated with insulin resistance and type 2 diabetes (wang2025multiplerolesof pages 1-2). Zhou et al. (2024) demonstrated that hepatic BCKDK promotes gluconeogenesis through CREB and FOXO1 signaling pathways independently of BCKDHA-mediated BCAA catabolism, as liver-specific BCKDHA knockout mice displayed normal glucose tolerance, while BCKDK knockout inhibited hepatic glucose production (flach2023smallmoleculebranchedchain pages 1-2). This finding separates the kinase's metabolic regulatory role from its canonical function of BCKDH phosphorylation.

6. Summary

BCKDHA encodes the catalytic E1α subunit of the mitochondrial BCKDH complex, the rate-limiting enzyme in branched-chain amino acid catabolism. As a thiamine pyrophosphate-dependent decarboxylase, it forms a heterotetrameric E1 component (α₂β₂) with BCKDHB that initiates the irreversible oxidative decarboxylation of BCKAs derived from leucine, isoleucine, and valine. The enzyme functions within the mitochondrial matrix as part of a massive multienzyme complex organized around a 24-meric E2 core. Its activity is tightly regulated by reversible phosphorylation at Ser293 (by BCKDK and PPM1K), by allosteric mechanisms including a recently discovered lncRNA activator (mitolnc), and by metabolon formation with the upstream enzyme BCAT2. Deficiency due to BCKDHA mutations causes maple syrup urine disease, while dysregulated BCKDH activity is increasingly implicated in cancer, cardiovascular disease, and metabolic syndrome, making it an emerging therapeutic target.

References

1. (OpenTargets Search: -BCKDHA): Open Targets Query (-BCKDHA, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (bo2024primaryrolesof pages 11-13): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

3. (szabo2024mitochondrialalphaketoacid pages 6-9): Eszter Szabó, Bálint Nagy, András Czajlik, T. Komlódi, Olivér Ozohanics, László Tretter, and A. Ambrus. Mitochondrial alpha-keto acid dehydrogenase complexes: recent developments on structure and function in health and disease. Sub-cellular biochemistry, 104:295-381, 2024. URL: https://doi.org/10.1007/978-3-031-58843-3_13, doi:10.1007/978-3-031-58843-3_13. This article has 16 citations.

4. (patrick2022metabolonformationregulates pages 1-3): McKenzie Patrick, Zhimin Gu, Gen Zhang, R. Max Wynn, Pranita Kaphle, Hui Cao, Hieu Vu, Feng Cai, Xiaofei Gao, Yuannyu Zhang, Mingyi Chen, Min Ni, David T. Chuang, Ralph J. DeBerardinis, and Jian Xu. Metabolon formation regulates branched-chain amino acid oxidation and homeostasis. Nature Metabolism, 4:1775-1791, Nov 2022. URL: https://doi.org/10.1038/s42255-022-00689-4, doi:10.1038/s42255-022-00689-4. This article has 51 citations and is from a domain leading peer-reviewed journal.

5. (weiss2024mitolnccontrolscardiac pages 14-15): Maria Weiss, Sara Hettrich, Theresa Hofmann, Salma Hachim, Stefan Günther, Thomas Braun, and Thomas Boettger. Mitolnc controls cardiac bcaa metabolism and heart hypertrophy by allosteric activation of bckdh. Nucleic Acids Research, 52:6629-6646, Apr 2024. URL: https://doi.org/10.1093/nar/gkae226, doi:10.1093/nar/gkae226. This article has 11 citations and is from a highest quality peer-reviewed journal.

6. (weiss2024mitolnccontrolscardiac pages 10-12): Maria Weiss, Sara Hettrich, Theresa Hofmann, Salma Hachim, Stefan Günther, Thomas Braun, and Thomas Boettger. Mitolnc controls cardiac bcaa metabolism and heart hypertrophy by allosteric activation of bckdh. Nucleic Acids Research, 52:6629-6646, Apr 2024. URL: https://doi.org/10.1093/nar/gkae226, doi:10.1093/nar/gkae226. This article has 11 citations and is from a highest quality peer-reviewed journal.

7. (mann2021branchedchainaminoacids pages 4-6): Gagandeep Mann, Stephen Mora, Glory Madu, and Olasunkanmi A. J. Adegoke. Branched-chain amino acids: catabolism in skeletal muscle and implications for muscle and whole-body metabolism. Frontiers in Physiology, Jul 2021. URL: https://doi.org/10.3389/fphys.2021.702826, doi:10.3389/fphys.2021.702826. This article has 312 citations.

8. (hawes1995rolesofamino pages 4-5): John W. Hawes, R. Jason Schnepf, Anne E. Jenkins, Yoshiharu Shimomura, Kirill M. Popov, and Robert A. Harris. Roles of amino acid residues surrounding phosphorylation site 1 of branched-chain α-ketoacid dehydrogenase (bckdh) in catalysis and phosphorylation site recognition by bckdh kinase. Journal of Biological Chemistry, 270(52):31071-31076, Dec 1995. URL: https://doi.org/10.1074/jbc.270.52.31071, doi:10.1074/jbc.270.52.31071. This article has 32 citations and is from a domain leading peer-reviewed journal.

9. (bo2024primaryrolesof pages 13-15): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

10. (szabo2024mitochondrialalphaketoacid pages 1-6): Eszter Szabó, Bálint Nagy, András Czajlik, T. Komlódi, Olivér Ozohanics, László Tretter, and A. Ambrus. Mitochondrial alpha-keto acid dehydrogenase complexes: recent developments on structure and function in health and disease. Sub-cellular biochemistry, 104:295-381, 2024. URL: https://doi.org/10.1007/978-3-031-58843-3_13, doi:10.1007/978-3-031-58843-3_13. This article has 16 citations.

11. (szabo2024mitochondrialalphaketoacid pages 9-13): Eszter Szabó, Bálint Nagy, András Czajlik, T. Komlódi, Olivér Ozohanics, László Tretter, and A. Ambrus. Mitochondrial alpha-keto acid dehydrogenase complexes: recent developments on structure and function in health and disease. Sub-cellular biochemistry, 104:295-381, 2024. URL: https://doi.org/10.1007/978-3-031-58843-3_13, doi:10.1007/978-3-031-58843-3_13. This article has 16 citations.

12. (szabo2024mitochondrialalphaketoacid pages 16-19): Eszter Szabó, Bálint Nagy, András Czajlik, T. Komlódi, Olivér Ozohanics, László Tretter, and A. Ambrus. Mitochondrial alpha-keto acid dehydrogenase complexes: recent developments on structure and function in health and disease. Sub-cellular biochemistry, 104:295-381, 2024. URL: https://doi.org/10.1007/978-3-031-58843-3_13, doi:10.1007/978-3-031-58843-3_13. This article has 16 citations.

13. (hawes1995rolesofamino pages 1-1): John W. Hawes, R. Jason Schnepf, Anne E. Jenkins, Yoshiharu Shimomura, Kirill M. Popov, and Robert A. Harris. Roles of amino acid residues surrounding phosphorylation site 1 of branched-chain α-ketoacid dehydrogenase (bckdh) in catalysis and phosphorylation site recognition by bckdh kinase. Journal of Biological Chemistry, 270(52):31071-31076, Dec 1995. URL: https://doi.org/10.1074/jbc.270.52.31071, doi:10.1074/jbc.270.52.31071. This article has 32 citations and is from a domain leading peer-reviewed journal.

14. (mann2021branchedchainaminoacids pages 9-11): Gagandeep Mann, Stephen Mora, Glory Madu, and Olasunkanmi A. J. Adegoke. Branched-chain amino acids: catabolism in skeletal muscle and implications for muscle and whole-body metabolism. Frontiers in Physiology, Jul 2021. URL: https://doi.org/10.3389/fphys.2021.702826, doi:10.3389/fphys.2021.702826. This article has 312 citations.

15. (szabo2024mitochondrialalphaketoacid pages 19-22): Eszter Szabó, Bálint Nagy, András Czajlik, T. Komlódi, Olivér Ozohanics, László Tretter, and A. Ambrus. Mitochondrial alpha-keto acid dehydrogenase complexes: recent developments on structure and function in health and disease. Sub-cellular biochemistry, 104:295-381, 2024. URL: https://doi.org/10.1007/978-3-031-58843-3_13, doi:10.1007/978-3-031-58843-3_13. This article has 16 citations.

16. (blair2021wholebodymetabolicfate pages 3-4): Megan C. Blair, Michael D. Neinast, and Zoltan Arany. Whole-body metabolic fate of branched-chain amino acids. The Biochemical journal, 478 4:765-776, Feb 2021. URL: https://doi.org/10.1042/bcj20200686, doi:10.1042/bcj20200686. This article has 45 citations.

17. (margutti2020maplesyrupurine pages 2-4): Ana Vitoria Barban Margutti, Wilson Araújo Silva, Daniel Fantozzi Garcia, Greice Andreotti de Molfetta, Adriana Aparecida Marques, Tatiana Amorim, Vânia Mesquita Gadelha Prazeres, Raquel Tavares Boy da Silva, Irene Kazue Miura, João Seda Neto, Emerson de Santana Santos, Mara Lúcia Schmitz Ferreira Santos, Charles Marques Lourenço, Tássia Tonon, Fernanda Sperb-Ludwig, Carolina Fischinger Moura de Souza, Ida Vanessa Döederlein Schwartz, and José Simon Camelo. Maple syrup urine disease in brazilian patients: variants and clinical phenotype heterogeneity. Orphanet Journal of Rare Diseases, Nov 2020. URL: https://doi.org/10.1186/s13023-020-01590-7, doi:10.1186/s13023-020-01590-7. This article has 18 citations and is from a peer-reviewed journal.

18. (campanholi2021molecularbasisof pages 1-2): Diana Ruffato Resende Campanholi, Ana Vitoria Barban Margutti, Wilson A. Silva, Daniel F. Garcia, Greice A. Molfetta, Adriana A. Marques, Ida Vanessa Döederlein Schwartz, V. Cornejo, Valerie Hamilton, Gabriela Castro, Fernanda Sperb‐Ludwig, Ester S. Borges, and José S. Camelo. Molecular basis of various forms of maple syrup urine disease in chilean patients. Molecular Genetics & Genomic Medicine, May 2021. URL: https://doi.org/10.1002/mgg3.1616, doi:10.1002/mgg3.1616. This article has 10 citations and is from a peer-reviewed journal.

19. (li2023identificationofgene pages 4-6): Lulu Li, Xinmei Mao, Nan Yang, Taoyun Ji, Shunan Wang, Yulan Ma, Haihe Yang, Yuting Sang, Jinqi Zhao, Lifei Gong, Yue Tang, and Yuanyuan Kong. Identification of gene mutations in six chinese patients with maple syrup urine disease. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1132364, doi:10.3389/fgene.2023.1132364. This article has 8 citations and is from a peer-reviewed journal.

20. (fang2021geneticanalysisby pages 4-5): Xiaohua Fang, Xiaofan Zhu, Yin Feng, Ying Bai, Xuechao Zhao, Ning Liu, and Xiangdong Kong. Genetic analysis by targeted next-generation sequencing and novel variation identification of maple syrup urine disease in chinese han population. Scientific Reports, Sep 2021. URL: https://doi.org/10.1038/s41598-021-98357-2, doi:10.1038/s41598-021-98357-2. This article has 10 citations and is from a peer-reviewed journal.

21. (weiss2024mitolnccontrolscardiac pages 12-14): Maria Weiss, Sara Hettrich, Theresa Hofmann, Salma Hachim, Stefan Günther, Thomas Braun, and Thomas Boettger. Mitolnc controls cardiac bcaa metabolism and heart hypertrophy by allosteric activation of bckdh. Nucleic Acids Research, 52:6629-6646, Apr 2024. URL: https://doi.org/10.1093/nar/gkae226, doi:10.1093/nar/gkae226. This article has 11 citations and is from a highest quality peer-reviewed journal.

22. (flach2023smallmoleculebranchedchain pages 1-2): Rachel J. Roth Flach, Eliza Bollinger, Allan R. Reyes, Brigitte Laforest, Bethany L. Kormos, Shenping Liu, Matthew R. Reese, Luis A. Martinez Alsina, Leanne Buzon, Yuan Zhang, Bruce Bechle, Amy Rosado, Parag V. Sahasrabudhe, John Knafels, Samit K. Bhattacharya, Kiyoyuki Omoto, John C. Stansfield, Liam D. Hurley, LouJin Song, Lina Luo, Susanne B. Breitkopf, Mara Monetti, Teresa Cunio, Brendan Tierney, Frank J. Geoly, Jake Delmore, C. Parker Siddall, Liang Xue, Ka N. Yip, Amit S. Kalgutkar, Russell A. Miller, Bei B. Zhang, and Kevin J. Filipski. Small molecule branched-chain ketoacid dehydrogenase kinase (bdk) inhibitors with opposing effects on bdk protein levels. Nature Communications, Aug 2023. URL: https://doi.org/10.1038/s41467-023-40536-y, doi:10.1038/s41467-023-40536-y. This article has 38 citations and is from a highest quality peer-reviewed journal.

23. (bo2024primaryrolesof pages 15-16): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

24. (cai2026branchedchainaminoacid pages 3-5): Dongchi Cai, Jialin Ji, Chunhui Yang, and Hong Cai. Branched-chain amino acid metabolic reprogramming and cancer: molecular mechanisms, immune regulation, and precision targeting. Oncology Research, 34(1):1-10, Jan 2026. URL: https://doi.org/10.32604/or.2025.071152, doi:10.32604/or.2025.071152. This article has 6 citations and is from a peer-reviewed journal.

25. (walejko2021branchedchainαketoacidsare pages 1-2): Jacquelyn M. Walejko, Bridgette A. Christopher, Scott B. Crown, Guo-Fang Zhang, Adrian Pickar-Oliver, Takeshi Yoneshiro, Matthew W. Foster, Stephani Page, Stephan van Vliet, Olga Ilkayeva, Michael J. Muehlbauer, Matthew W. Carson, Joseph T. Brozinick, Craig D. Hammond, Ruth E. Gimeno, M. Arthur Moseley, Shingo Kajimura, Charles A. Gersbach, Christopher B. Newgard, Phillip J. White, and Robert W. McGarrah. Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart. Nature Communications, Mar 2021. URL: https://doi.org/10.1038/s41467-021-21962-2, doi:10.1038/s41467-021-21962-2. This article has 112 citations and is from a highest quality peer-reviewed journal.

26. (sun2020identificationofeight pages 4-5): Wei-Hua Sun, Bing-Bing Wu, Ya-Qiong Wang, Meng-Yuan Wu, Xin-Ran Dong, Yue-Ping Zhang, Wei Lu, Ping Zhang, Bin Yang, Min Zhang, Hong-Jiang Wu, and Wen-Hao Zhou. Identification of eight novel mutations in 11 chinese patients with maple syrup urine disease. World Journal of Pediatrics, pages 1-10, Mar 2020. URL: https://doi.org/10.1007/s12519-020-00349-1, doi:10.1007/s12519-020-00349-1. This article has 12 citations and is from a peer-reviewed journal.

27. (du2022theroleof pages 6-7): Chuang Du, Wen-Jie Liu, Jing Yang, Shan-Shan Zhao, and Hui-Xin Liu. The role of branched-chain amino acids and branched-chain α-keto acid dehydrogenase kinase in metabolic disorders. Frontiers in Nutrition, Jul 2022. URL: https://doi.org/10.3389/fnut.2022.932670, doi:10.3389/fnut.2022.932670. This article has 98 citations.

28. (cai2026branchedchainaminoacid pages 5-7): Dongchi Cai, Jialin Ji, Chunhui Yang, and Hong Cai. Branched-chain amino acid metabolic reprogramming and cancer: molecular mechanisms, immune regulation, and precision targeting. Oncology Research, 34(1):1-10, Jan 2026. URL: https://doi.org/10.32604/or.2025.071152, doi:10.32604/or.2025.071152. This article has 6 citations and is from a peer-reviewed journal.

29. (li2025proteinlipoylationin pages 3-4): Sainan Li, Yingchao Liu, Wanye Hu, Aoli Deng, Xueying Ren, Lulu Chen, Yajuan Lu, Yunyi Wu, Hangqi Huang, Jinghao Cao, Jing Du, Jun Xia, and Yanchun Li. Protein lipoylation in cancer: metabolic reprogramming and therapeutic potential. Cell Death Discovery, Sep 2025. URL: https://doi.org/10.1038/s41420-025-02718-z, doi:10.1038/s41420-025-02718-z. This article has 12 citations and is from a peer-reviewed journal.

30. (cai2026branchedchainaminoacid pages 27-28): Dongchi Cai, Jialin Ji, Chunhui Yang, and Hong Cai. Branched-chain amino acid metabolic reprogramming and cancer: molecular mechanisms, immune regulation, and precision targeting. Oncology Research, 34(1):1-10, Jan 2026. URL: https://doi.org/10.32604/or.2025.071152, doi:10.32604/or.2025.071152. This article has 6 citations and is from a peer-reviewed journal.

31. (wang2025multiplerolesof pages 1-2): Lin Wang, Feng Shi, Ya Cao, and Longlong Xie. Multiple roles of branched-chain amino acid metabolism in tumour progression. Journal of Biomedical Science, Apr 2025. URL: https://doi.org/10.1186/s12929-025-01132-y, doi:10.1186/s12929-025-01132-y. This article has 13 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. bo2024primaryrolesof pages 11-13
2. patrick2022metabolonformationregulates pages 1-3
3. mann2021branchedchainaminoacids pages 4-6
4. szabo2024mitochondrialalphaketoacid pages 9-13
5. szabo2024mitochondrialalphaketoacid pages 6-9
6. hawes1995rolesofamino pages 4-5
7. szabo2024mitochondrialalphaketoacid pages 1-6
8. szabo2024mitochondrialalphaketoacid pages 16-19
9. weiss2024mitolnccontrolscardiac pages 10-12
10. mann2021branchedchainaminoacids pages 9-11
11. hawes1995rolesofamino pages 1-1
12. bo2024primaryrolesof pages 13-15
13. bo2024primaryrolesof pages 15-16
14. weiss2024mitolnccontrolscardiac pages 14-15
15. blair2021wholebodymetabolicfate pages 3-4
16. cai2026branchedchainaminoacid pages 3-5
17. flach2023smallmoleculebranchedchain pages 1-2
18. campanholi2021molecularbasisof pages 1-2
19. du2022theroleof pages 6-7
20. cai2026branchedchainaminoacid pages 5-7
21. wang2025multiplerolesof pages 1-2
22. szabo2024mitochondrialalphaketoacid pages 19-22
23. margutti2020maplesyrupurine pages 2-4
24. li2023identificationofgene pages 4-6
25. fang2021geneticanalysisby pages 4-5
26. weiss2024mitolnccontrolscardiac pages 12-14
27. sun2020identificationofeight pages 4-5
28. li2025proteinlipoylationin pages 3-4
29. cai2026branchedchainaminoacid pages 27-28
30. https://doi.org/10.3390/molecules30010056,
31. https://doi.org/10.1007/978-3-031-58843-3_13,
32. https://doi.org/10.1038/s42255-022-00689-4,
33. https://doi.org/10.1093/nar/gkae226,
34. https://doi.org/10.3389/fphys.2021.702826,
35. https://doi.org/10.1074/jbc.270.52.31071,
36. https://doi.org/10.1042/bcj20200686,
37. https://doi.org/10.1186/s13023-020-01590-7,
38. https://doi.org/10.1002/mgg3.1616,
39. https://doi.org/10.3389/fgene.2023.1132364,
40. https://doi.org/10.1038/s41598-021-98357-2,
41. https://doi.org/10.1038/s41467-023-40536-y,
42. https://doi.org/10.32604/or.2025.071152,
43. https://doi.org/10.1038/s41467-021-21962-2,
44. https://doi.org/10.1007/s12519-020-00349-1,
45. https://doi.org/10.3389/fnut.2022.932670,
46. https://doi.org/10.1038/s41420-025-02718-z,
47. https://doi.org/10.1186/s12929-025-01132-y,